ADCETRIS (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

11.12.2023 - Seagen Inc. (NASDAQ: SGEN) today announced that clinically meaningful progression-free survival (PFS), a secondary endpoint, was observed in a Phase 2 study evaluating the antibody-drug conjugate (ADC) ADCETRIS (brentuximab vedotin) in combination ... Seite 1

Related Keywords

San Diego ,California ,United States ,Massachusetts ,American ,Jeremy Abramson ,Jo Ann Hagler Center ,Nasdaq ,American Society Of Hematology Annual Meeting Exposition ,Seagen Inc ,American Society ,Hematology Annual Meeting ,Massachusetts General Hospital ,Seagen Chart ,Eagen Kurs ,Eagen Aktie ,